IGF2BP1 and prostate adenocarcinoma: We ascertained IGF2BP1 was significantly upregulated in most cancer types as compared with the corresponding normal tissues, but not in adrenocortical carcinoma (ACC), kidney, renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), pheochromocytoma and paraganglioma (PCPG), and prostate adenocarcinoma (PRAD) (Figure 2A).